Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totalling 1,700 shares, a decline of 22.7% from the March 15th total of 2,200 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 6,100 shares, the short-interest ratio is presently 0.3 days.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Susquehanna International Group LLP raised its stake in Xenetic Biosciences Inc (NASDAQ:XBIO) by 210.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,819 shares of the company’s stock after acquiring an additional 52,779 shares during the period. Susquehanna International Group LLP owned 0.51% of Xenetic Biosciences worth $32,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 15.12% of the stock is owned by institutional investors and hedge funds.

Xenetic Biosciences Stock Performance

NASDAQ:XBIO opened at $4.33 on Friday. Xenetic Biosciences has a 1 year low of $2.55 and a 1 year high of $5.97. The stock has a market cap of $6.67 million, a P/E ratio of -1.57 and a beta of 2.60. The stock has a 50-day simple moving average of $4.06 and a 200-day simple moving average of $3.77.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.